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Abstract
Osteoarthritis (OA) and rheumatoid arthritis (RA) are both debilitating diseases that cause significant morbidity in
the US population. Extracellular vesicles (EVs), including exosomes and microvesicles, are now recognized to play
important roles in cell-to-cell communication by transporting various proteins, microRNAs (miRNAs), and mRNAs.
EV-derived proteins and miRNAs impact cell viability and cell differentiation, and are likely to play a prominent role
in the pathophysiology of both OA and RA. Some of the processes by which these membrane-bound vesicles can
alter joint tissue include extracellular matrix degradation, cell-to-cell communication, modulation of inflammation,
angiogenesis, and antigen presentation. For example, EVs from IL-1β-stimulated fibroblast-like synoviocytes have
been shown to induce osteoarthritic changes in chondrocytes. RA models have shown that EVs stimulated with
inflammatory cytokines are capable of inducing apoptosis resistance in T cells, presenting antigen to T cells, and
causing extracellular damage with matrix-degrading enzymes. EVs derived from rheumatoid models have also
been shown to induce secretion of COX-2 and stimulate angiogenesis. Additionally, there is evidence that
synovium-derived EVs may be promising biomarkers of disease in both OA and RA. The characterization of EVs
in the joint space has also opened up the possibility for delivery of small molecules. This article reviews current
knowledge on the role of EVs in both RA and OA, and their potential role as therapeutic targets for modulation
of these debilitating diseases.
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Background
Osteoarthritis (OA) and rheumatoid arthritis (RA) are
prevalent causes of morbidity and disability worldwide.
OA is estimated to affect 3.8% (95% CI: 3.6–4.1) of the
world’s population, with the United States having an
even higher prevalence [1]. Characteristics of this disease
include degraded cartilage, moderate synovial inflamma-
tion, alteration of bony structure, pain, and impaired
mobility [2]. Pain management and weight loss provide
some relief, yet these interventions do not halt the pro-
gression of the disease. Knee arthroplasty removes the
arthritic tissue but 10–20% of patients still report that
pain remains after surgery [3]. RA in northern Europe
and the United States has a prevalence of 0.5–1% [4].
The disease is characterized by swelling, tenderness, and
destruction of synovial joints [5, 6]. Auto-antibodies
such as rheumatoid factor and anti-citrullinated protein
antibody help to detect the presence of the disease
before it presents clinically [7]. Disease-modifying anti-
rheumatic drugs such as methotrexate and newer bio-
logic agents have helped to improve the prognosis and
prevent the progression of RA; however, despite the se-
verity of both of these diseases, relatively little is known
about the complex pathogenesis.
Recently, membrane-bound microparticles/microvesi-
cles, apoptotic bodies, and exosomes—collectively known
as extracellular vesicles (EVs)—have been identified and
shown to carry microRNA (miRNA), mRNA, and protein
[8–10]. The three broad categories of EVs are distin-
guished based on their biogenesis. Microparticles/micro-
vesicles are formed by outward budding and fission of the
plasma membrane [11]. Exosomes are created in the
endosomal network of the cell and released by the fusion
of multivesicular bodies with the plasma membrane [11].
Apoptotic bodies are formed as cells undergo apoptosis
and release their contents in membrane-bound vesicles
[11]. It is difficult to distinguish these three subgroups of
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EVs. Size was once thought to be a major determining fac-
tor, where vesicles larger than 100 nm were thought to be
microvesicles and vesicles smaller than 100 nm were gen-
erally considered exosomes [12]. However, recent research
has shown that the size of these particles overlaps with
each other [12]. Protein composition determination is a
major mechanism of identification of these particles and is
the most widely accepted [13]. While protein composition
is helpful, there is no single marker whose presence or ab-
sence can define the type of EVs [11]. Tetraspanins CD9,
CD63, and CD81 were at one point thought to be specific
to exosomes but this has now been disproven [11]. Es-
tablishment of multiple public databases that profile
the protein composition of different EVs has helped
with the identification process [14]. The term exosome
is often used generally to reference these membrane-
bound particles, and there has been a large increase in
publications on exosomes since 2010 [13, 15]. In the
absence of a standard approach to isolating exosomes
sensu stricto, this review will refer to these small,
membrane-bound particles as EVs.
EVs are known to function in cell-to-cell communica-
tion and are able to transmit their contents to different
cells and cause various changes in cell transcription and
cell proliferation [16–20]. They have also been shown to
vary in their contents, specifically miRNA, in different
disease states to the degree that a patient’s EV miRNA
expression profile can serve as a potential biomarker
[21–23]. Previous research indicates that EV content is
altered in pathologic conditions of RA and OA [24, 25].
This review aims to highlight current knowledge on the
role of EVs in OA and RA.
Extracellular vesicles in the development and
pathogenesis of RA
The role of EVs in the pathogenesis of RA is beginning
to be better understood. Some of the pathogenic pro-
cesses in which EVs have been implicated with regard to
the development of RA include formation of immune
complexes, antigen presentation, delivery of miRNA, in-
flammatory cytokines, proteases, and other proteins, ac-
tivation of fibroblast-like synoviocytes (FLS), cell-to-cell
communication, and degradation of the extracellular
matrix (Table 1) [26].
Antigen presentation and immune complex formation
EVs present antigens that result in antibody formation
characteristic of RA [27]. Detection of different autoanti-
bodies offers different degrees of sensitivity and specifi-
city for detecting RA. The presence of anti-cyclic
citrullinated peptide (anti-CCP) antibodies in the serum
has a specificity of 96% for the diagnosis of RA and is
one of the most useful biomarkers currently available
[7]. Citrulline is a neutral amino acid that is formed fol-
lowing deimination of protein-bound arginine by the
peptidylarginine deiminase family of enzymes (PADs)
[28]. PADs are a family of calcium-dependent enzymes
that have been implicated in the pathogenesis of cancer
progression and a wide range of autoimmune diseases
[28]. FLS-derived EVs have been shown to carry citrulli-
nated proteins such as fibrinogen components, vimentin,
and apoptosis inhibitor of the macrophage (AIM) in
their membrane [27]. This cargo stimulates antibodies to
these proteins and the formation of immune complexes
[27, 29–31]. Other studies have demonstrated that




Present antigens for recognition by immune cells. Proteins such as DEK, vimentin, fibrin, fibronectin, fibrinogen,
and AIM are present in the membrane. These become citrullinated and are thought to activate the innate and
adaptive immune system, resulting in inflammation. Additionally these antibodies form to these complexes and
deposit in the tissues, resulting in increased inflammation [27, 31, 35]
Inflammation Carry membrane-bound TNF-α, which causes inflammation. EVs stimulate production of TNF-α, IL-6, IL-8, and mPGES-1,
further increasing inflammation. Platelet-derived EVs are found in patients with RA and increase inflammation in an IL-1
receptor-mediated mechanism. Presence of EV-based immune complexes causes increased inflammation. EVs can
activate TLR4, which triggers anti-inflammatory genes. EVs carry ANXA1 which reduces inflammatory cytokines
[24, 36–38, 41, 43, 47]
Destruction of ECM Carry catabolic proteases such as MMPs, ADAMTS-5, Hexosaminidase D, and B-glucuronidase. This causes the breakdown
of ECM, resulting in the destruction of cartilage and more inflammation. ANXA1 in EVs activates anabolic genes in
chondrocytes [47, 51–57]
Biomarker Differences in content of synovial fluid and plasma EVs can serve as a biomarker for disease. There has proven to be
an increased concentration of EVs in plasma of people with RA. Additionally, the presence of citrullinated proteins in
EV membrane is a potential biomarker that is specific to RA [27, 41, 58]
Delivery of miRNA Deliver miRNA to cells altering response to inflammation. Dendritic cells are known to secrete EVs with increased
levels of miR-155 and miR-146a in response to inflammation [58–65]
Therapeutic EVs derived from IL-10-treated dendritic cells have shown anti-inflammatory properties in patients with RA. EVs have
also been created that can target the synovial membrane specifically. Demonstration that EVs have anti-inflammatory
properties illustrates the possibility of mimicking that stimulation therapeutically [43, 47, 79–81]
AIM apoptosis inhibitor of the macrophage, ANXA1 annexin A1, DEK DNA-binding protein, ECM extracellular matrix, EV extracellular vesicle, miRNA microRNA,
MMP matrix metalloproteinase, mPGES-1 microsomal prostaglandin E synthase 1, RA rheumatoid arthritis, TLR4 Toll-like receptor 4
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synovial fluid-derived EVs originating from different cells
also form immune complexes. A large subset of the EV-
based immune complexes found was CD41+, which is a
platelet marker, suggesting that there is a large cohort of
immunogenic EVs that are derived from platelets [31].
Immune complexes formed around EVs cause marked
upregulation of leukotriene production from neutrophils
in vitro, indicating that they contribute to inflammation
[31]. Nielsen et al. also demonstrated EV-based immune
complex formation in rheumatologic diseases. This study
showed that plasma from patients with RA had signifi-
cantly more IgM attached to circulating EVs than plasma
from controls [32]. Deposition of immune complexes in
tissues is recognized as one of the major mechanisms of
inflammation in rheumatic diseases [31, 33, 34]. EVs
have also been shown to function in antigen presenta-
tion [35]. EVs containing DNA-binding protein (DEK)
are known to deliver this antigen to CD8+ lymphocytes
and NK cells [35]. This results in a more efficient anti-
gen presentation and can result in increased activation
of the immune system [35].
Inflammation
EVs derived from the joints of patients with RA have
been shown to induce inflammatory changes in chon-
drocytes in vitro [24, 36]. A membrane-bound form of
TNF-α is present in EVs derived from FLS isolated from
RA patients [37]. Activation of FLS by the membrane-
bound TNF-α in EVs results in activation of NF-κB
which promotes inflammation and renders T cells found
in the synovial tissue resistant to apoptosis [37]. Further-
more, EVs isolated from TNF-α-treated T cells and
monocytes have been shown to stimulate FLS produc-
tion of cyclooxygenase 2 (COX-2), microsomal prosta-
glandin E synthase 1 (mPGES-1), and prostaglandin E2
(PGE2) [38]. COX-2 converts arachadonic acid to in-
flammatory mediators such as PGE2 that are known to
cause inflammation and pain [39]. Interestingly, these
EVs were found to transport arachidonic acid to the FLS
for conversion into inflammatory mediators by FLS-
derived COX-2 [38]. In addition to the enzymes that are
induced, the proinflammatory nuclear transcription fac-
tors NF-κB, AP-1, and JNK are also increased in the FLS
after treatment with EVs isolated from TNF-α-treated T
cells and monocytes [38]. Inhibition of the NF-κB and
AP-1 pathway prevents the activation of mPGES-1 but
not COX-2 [38]. However, inhibition of JNK did block
the activation of COX-2, indicating that the JNK path-
way is responsible for microsomal activation of COX-2
and subsequently PGE2 [38].
EVs derived from TNF-α-treated monocytes and T cells
can directly stimulate the FLS secretion of inflammatory
mediators such as IL-6 and IL-8 [38]. These mediators are
known to contribute substantially to inflammation in
patients with RA, and blocking IL-6 is one treatment for
RA resistant to conventional therapies [40]. An additional
finding that suggests EVs play a significant role in the in-
flammation caused by RA is that platelet-derived EVs were
found in the synovial fluid of patients with RA, and not
found in patients with OA [41]. The glycoprotein VI re-
ceptor, which is a collagen receptor, is the key receptor for
the induction of EV production by platelets [41]. The EVs
from the platelets were shown to promote inflammation
via the IL-1 receptor in FLS [41].
Toll-like receptor 4 (TLR-4) and its coreceptor MD-2
are known to contribute to inflammation in a large
number of diseases, including RA [42–46]. Further sup-
porting the role of this receptor in the development of
RA are studies showing that mice deficient in TLR4 are
protected from developing experimentally induced arth-
ritis, and that blocking the TLR4 receptor is a successful
therapeutic in treating experimentally induced arthritis
[43–46]. LPS is known to activate the signal transduc-
tion of TLR4, but the search for endogenous activators
of this pathway has previously been unsuccessful.
Plasma-derived EVs from patients with RA stimulated
this receptor via a similar mechanism to LPS, that is by
increasing activity of the TLR4 pathway significantly
more than EVs from healthy subjects [42]. Further stud-
ies were carried out to confirm that it was truly through
the TLR4 pathway, in which applying the same EVs to
monocytes with a point mutation in the LPS binding do-
main of the receptor failed to induce inflammation [42].
Investigation into the specific mechanism of activation
revealed that oxidized phospholipids in the membrane
of EVs were responsible for the stimulation of the recep-
tor [42]. Interestingly, when the effect of oxidized EVs
on monocyte gene expression was examined, it was
shown that the gene expression profile was markedly dif-
ferent than that of the cells stimulated with LPS [42].
The gene expression profile was analyzed in relation to
genes associated with RA and found that there was
substantial induction of inflammation resolving genes,
notably IL-4 which promotes repair and decreases in-
flammation [42]. This differs from other work described
previously which suggests the involvement of EVs in fur-
thering inflammation. The EVs in this study seem to
function as an oxidative-stress warning signal to the tis-
sues to resolve inflammation. Of note, previous work
has indicated that citrullinated immune complexes, a
finding present in nearly 100% of RA patients, stimulate
the TLR4 receptor to induce TNF-α significantly more
effectively than uncomplexed citrullinated proteins [34].
The disruption of the balance of anti-inflammatory EV
stimuli and inflammatory EV stimuli at the TLR- recep-
tor represents a potential source of some of the in-
flammation associated with RA that deserves further
investigation.
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Another study has corroborated what Mancek-Keber
et al. [46] reported about EVs helping to resolve inflam-
mation. EVs were isolated from synovial fluid of patients
with RA, and the proportions of EVs originating from
neutrophils, monocytes, and T cells were characterized
using different cell surface markers specific to each cell
line [47]. Neutrophils contributed to the EVs in the syn-
ovial fluid but the concentration of all of the cell line-
derived EVs was elevated significantly compared with
the plasma [47]. A higher percentage of synovial fluid
EVs contained the anti-inflammatory protein annexin
A1 (ANXA1) compared with plasma-derived EVs [47].
ANXA1 has been shown to have anti-inflammatory ef-
fects, although the mechanism of action of this protein
was not known previously [47–50]. A mouse model de-
ficient in neutrophil EVs demonstrated twice the
amount of cartilage loss when subjected to inflamma-
tory arthritis compared with mice that had this mech-
anism intact [47]. ANXA1-containing EVs applied to
chondrocytes in vitro activated anabolic genes, resulting
in accumulation of ECM and a reduction in inflamma-
tory cytokines IL-8 and PGE-2 [47]. This finding was
supported by an in-vivo mouse study where ANXA1-
containing EVs injected into the joint space of mice
with experimental induced inflammatory arthritis re-
sulted in significantly less cartilage destruction than the
control group [47]. Mice given neutrophils via adoptive
transfer demonstrated abundant EVs in the joint space
but no neutrophils, indicating that the neutrophils de-
liver their EVs to the joint space without penetrating
the synovial membrane [47]. Because little was known
about the mechanism of action of ANXA1, further
studies were undertaken to elucidate the mechanism.
These studies demonstrated that ANXA1 is a ligand
for the formyl peptide receptor 2 (FPR2/ALX) on
chondrocytes, which when stimulated results in in-
crease TGF-β by the chondrocytes [47]. The upregula-
tion of ECM production is blocked by a specific FPR2
inhibitor, suggesting that the upregulation of ECM is
truly caused by ANXA1 [47]. This upregulation oc-
curred both with and without costimulation with IL-
1β, indicating that the process is not suppressed by
inflammation and making it an interesting therapeutic
target for both RA and OA [47].
Destruction of ECM
EVs derived from monocytes and T cells treated with
TNF-α induce the production of large quantities of matrix
metalloproteinase-1 (MMP-1), MMP-3, MMP-9, and
MMP-13 by FLS [51–53]. MMPs, especially MMP-13,
break down proteoglycans, such as aggrecan and collagen,
in the ECM and are thought to be a major mechanism of
cartilage destruction in RA [51, 53]. Interestingly, blocking
the TNF-α and IL-1β receptor did not mitigate the
response by FLS, indicating that EV-induced inflammation
is independent of TNF-α-induced inflammation and ECM
breakdown [51]. RA-derived FLS secrete EVs that con-
tained high levels of ADAMTS-5 [54]. This further indi-
cates that EVs released from synovial tissues have the
capability to directly break down joint tissue, thereby fur-
ther contributing to joint destruction. Moreover, EVs iso-
lated from endothelial cells carry MMP-2, MMP-9, and
MMP-14, indicating involvement of EVs in the breakdown
of capillary membrane contributing to fluid build-up,
swelling, and transfer of cells and proteins from the joint
space into systemic circulation [55].
Hexosaminidase D and B-glucuronidase are enzymes
with similar activity to aggrecanase, and are present in
EVs in the joint space of patients with both RA and OA
[56, 57]. While hexosaminidase enzymes generally have
a wide substrate profile, making it hard to identify which
particular enzyme causes the destruction, hexosamini-
dase D is elevated in synovial fluid EVs of both patients
with RA and OA [56, 57]. B-glucuronidase has enzym-
atic activity in EVs derived from both RA and OA pa-
tients [56, 57]. Previously, this was thought to be a
housekeeping gene but its localization in the EVs indi-
cates that it is involved in regulation of ECM turnover
[56, 57]. This represents yet another catabolic process in
the development of RA that may involve EVs.
miRNA delivery
It is now recognized that miRNAs play a role in RA patho-
physiology. The most well-known miRNAs involved in the
pathophysiology of RA are miR-155 and miR-146a (Fig. 1).
miR-155 is upregulated in the FLS of patients with RA
compared with OA patients and normal controls, and
inhibition of miR-155 in FLS results in decreased TNF-α
production in vivo [58, 59]. Additionally, miR-155
Fig. 1 TNF-α in the joint fluid stimulates FLS to increase microRNAs
miR-155 and miR-146. miR-155 stimulates production of Src homology
2-containing inositol phosphatase-1 (SHIP-1), Fas-associated death
domain protein (FADD), and Serine-threonine kinase 1 (Ripk1) to
promote inflammation and increase TNF-α production by the FLS.
miR-146a downregulates TNF receptor associated factor 6 (TRAF6) and
IL-1 receptor associated kinase 1 (IRAK1) to suppress inflammation and
decrease TNF-α production. Additionally, these miRNA are found in the
joint space of patients with RA and increased in EVs released by
dendritic cells in response to inflammation
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knockout mice are resistant to the development of
collagen-induced arthritis, while overexpression of
miR-155 in mice results in a chronic inflammatory state
with increased production of inflammatory cytokines
[58]. miR-155 is stimulated by TNF-α and LPS, further
implicating its role in the development of RA [60].
Modulation of inflammation is accomplished by target-
ing the transcripts of Src homology 2-containing inosi-
tol phosphatase-1 (SHIP-1), Fas-associated death
domain protein (FADD), IκB kinase ε (IKKε), and
serine-threonine kinase 1 (Ripk1), which interact with
the TNF-α receptor and upregulate TNF-α translation
[58, 60]. Interestingly, overexpression of miR-155 re-
sults in inhibition of MMP-13 production in response
to inflammatory stimuli [59]. miR-146a is upregulated
in the FLS of patients with RA compared with patients
with OA and normal controls [61]. In-vivo studies show
that miR-146a is upregulated in FLS by TNF-α and by
IL-1β [61]. miR-146a overexpression suppresses IL-6
and IL-8 secretion and downregulates the IL-1 receptor
associated kinase 1 (IRAK1) and TNF receptor associ-
ated factor 6 (TRAF6) genes [61–63]. Overexpression
mouse models exhibit a decreased immune response by
monocytes when challenged with LPS, while knockout
mice models show an increased production of TNF-α,
Il-6, and IL-1β when treated with LPS [64].
miR-155 and miR-146a are also found in EVs released
by dendritic cells and taken up by all immune cells [65].
miR-146a reduces inflammatory gene expression in den-
dritic cells while miR-155 promotes inflammatory gene
expression [65]. This finding was replicated in a mouse
model, supporting the functional importance of this path-
way in mediating inflammation [65]. miR-155 knockout
mice were given an LPS challenge following administra-
tion of EVs loaded with miR-155. The control mice exhib-
ited no inflammation following the challenge whereas the
EV-treated mice exhibited inflammation and had detect-
able levels of miR-155 in all immune cells in addition to
elevated TNF-α and IL-6 levels [65]. miR-146a knockout
mice that underwent the same experiment showed large
levels of inflammation and the EV-loaded miR-146a-
treated mice showed lower levels of TNF-α and IL-6 [65].
Again, all immune cells had detectable levels of miR-146a,
demonstrating the importance of this pathway in modu-
lating the immune response [65]. Furthermore, the pres-
ence of EVs containing miR-155 and miR-146a in an
inflammatory state suggests possible crosstalk between
dendritic cells and FLS. While the exact mechanism by
which EVs are taken up by immune cells may be cell spe-
cific, a few different mechanisms have been demonstrated.
It is clear that EVs do possess different adhesion molecules
that facilitate their interaction with immune cells such
as the integrins ανβ3 and ανβ5, ICAM1, and LFA1
[66–71]. Interestingly, it has been shown that MHC II
and ICAM1 are required for EVs to activate naïve T cells
[70]. Membrane fusion at the cell surface has also been
demonstrated as one uptake mechanism of EVs, which re-
sults in the direct transfer of proteins to the plasma mem-
brane surface. Current literature indicates that a majority
of the EVs are phagocytosed [11, 72–74]. Alternatively,
macropinocytosis has also been shown to be a potential
mechanism of uptake [11, 75]. Once inside the cell, the
EV either fuses membranes with the endosome or is de-
graded in the lysosome [11]. If fusion occurs, the proteins
can be recycled and presented on the accepting cells
membrane [11]. Further work is needed to determine the
exact mechanism of EV uptake by specific cell types.
Biomarker of disease
Current data suggest that EVs may serve as biomarkers
for rheumatic diseases. Serum levels of EVs are elevated
in RA compared with healthy controls [76]. Additionally,
the protein content of EVs from patients with RA is al-
tered [27]. Synovial fluid and serum EVs from patients
with RA contain 10 different proteins specific to RA EVs
that are not found in patients with OA or reactive arth-
ritis [27]. Over half of these proteins were also found in
the citrullinated form, further increasing the specificity
of these proteins as diagnostic tools [27]. Recent recog-
nition of the differences in miRNA EV signatures in dif-
ferent disease states provides a promising new method
to detect RA earlier and more accurately [21–23, 77].
An extensive profiling of EVs from the plasma and joint
fluid of RA patients and healthy controls might reveal
new biomarkers associated with RA disease progression
and response to treatment.
Extracellular vesicles as therapeutic vehicles for the
treatment of RA
EVs have already shown therapeutic potential in patients
with RA. In a collagen-induced arthritis model, EVs con-
taining IL-10 and EVs derived from dendritic cells
treated with IL-10 have strong anti-inflammatory prop-
erties when isolated, purified, and injected periarticularly
[78]. Surprisingly, this change occurs not only at the
injected joint but also at the contralateral joint even
when injected locally, indicating that there is systemic
circulation of EVs [78]. This finding was replicated when
the EVs were injected systemically [78]. Local injection
in the joints of the murine model with dendritic cells
transfected with IL-10 suppresses inflammation both lo-
cally and in contralateral joints [78].
Vanniasinghe et al. [79] recently described targeting li-
posomes, small artificial vesicles with similar properties
to EVs, to FLS. Therapeutically, liposomes are similar to
EVs in the sense that they can be loaded with cargo, are
biocompatible, and demonstrate the ability to get into
cells [80]. Liposomes differ from exosomes in that their
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membranes are significantly less complex, their circulation
time is adjustable depending on the composition, and the
ability to target cells may be limited [80]. Vanniasinghe et
al. [79] successfully delivered immunosuppressive therapy
in the form of glucocorticoids to the synovial membrane
and saw a dramatic reduction in inflammation in a
collagen-induced arthritis model. This demonstrates a
novel therapeutic technique that can be used to target in-
flamed synovial joints without the unwanted side-effect
profile of steroid medication. Systemic side effects have
been a huge hurdle in therapeutics for RA, particularly the
newer biologics. While these therapies are useful for con-
trolling the disease symptoms of RA, they leave patients
chronically immunosuppressed, which can increase risk
for infection. Targeting synovial joints systemically by lipo-
somes for delivery of therapeutics such as biologics could
result in improved efficacy of current treatment, drastic-
ally improved side effect profile of current treatments, and
an opportunity for new therapeutics that can further alter
the course of RA.
The recent studies suggesting that EVs serve as a
warning signal and are actively involved in reducing in-
flammation obviously differ from those studies showing
that EVs contribute to the inflammation of RA. Taken
together it is apparent that the role of EVs in the patho-
genesis of RA is dependent on the type of cells from
which the EVs are derived. The studies indicating that
EVs are involved in a physiologic response to limit in-
flammation further emphasize the potential utility of
EVs as therapeutics for RA. Developing a therapeutic
that can mimic or amplify a natural response to decrease
inflammation represents a promising therapeutic target.
Extracellular vesicles in the development and
pathogenesis of OA
A role for EVs in OA is less well documented than for
RA. The pathogenesis of OA is complex, and both the
chondrocytes themselves and the extracellular matrix
(ECM) are crucial to maintain healthy articular cartil-
age [81, 82]. The ECM is vital to the maintenance of ar-
ticular cartilage because it has a very low cell density,
which is critical for the functional properties of the
tissue [82]. The ECM is largely made up of type II
collagen and proteoglycans, in particular aggrecan [83].
Chondrocytes are solely responsible for the synthesis of
aggrecan, which subsequently becomes articular cartilage
[82]. FLS are responsible for secreting joint fluid that
lubricates the articular cartilage. In healthy articular cartil-
age, a balance between synthesis and breakdown of the
ECM maintains cartilage integrity [82, 84]. This specific
balance between synthesis and degradation of the ECM is
disturbed in the pathological condition of OA [84], such
that ECM synthesis can no longer compensate for the loss
of matrix structural integrity. The disease process pro-
gresses to the point where clinical symptoms arise, such
as pain, bone-on-bone grinding, osteophyte formation,
and joint space narrowing [85]. The specific mechanism
by which that balance is disturbed is multifactorial and
has not yet been fully elucidated. MMPs are a family of
proteinases that are believed to contribute largely to
the breakdown of ECM, in particular MMP-13 [86–88].
Currently MMP-13 is thought to be the major mediator
of ECM breakdown that causes the majority of the
pathology seen in OA and is produced by both chon-
drocytes and FLS [89–91]. MMP-13-deficient mice are
resistant to collagen and aggrecan breakdown, which
subsequently prevents cartilage erosion [91]. This en-
zyme is induced by the inflammatory cytokines IL-1β
and TNF-α in the joint space [92, 93].
Role of EVs in communication between FLS and
chondrocytes
OA involves many different cell types, and until recently
little has been known about cellular communication be-
tween different cell lineages. EVs serve as a communica-
tion pathway between different tissue types and between
different cell types, and thus represent a crucial step in
the regulation of the disease process (Table 2) [17, 18].
When EVs derived from chondrocytes treated with IL-
1β are applied to FLS, there is a nearly 3-fold increase in
MMP-13 production as compared with EVs derived
from chondrocytes without IL-1β stimulation (Fig. 2)
[94]. Additionally, there is markedly increased produc-
tion of IL-1β, TNF-α, and COX-2 by the synovial mem-
brane, indicating that the EVs are playing a role in the
inflammatory component of OA [94].




FLS EVs are known to be secreted into the joint space and are taken up by chondrocytes. EVs isolated from
chondrocytes treated with inflammatory cytokines are known to increase inflammatory cytokine production and
MMP-13 production by FLS. EVs isolated from FLS treated with inflammatory cytokines are known to increase
inflammatory cytokine production and MMP-13 production by chondrocytes [25, 94, 98]
Biomarker Differences in content of synovial fluid and plasma EVs can serve as a biomarker for disease. miR-200c is elevated
compared with non-OA patients [98]
Therapeutic Deliver miRNA to cells altering response to inflammation. Potential to target the reduction of MMP-13 production
using miRNA. Additionally, EVs could be used to induce chondrogenesis.
EV extracellular vesicle, FLS fibroblast-like synoviocytes, miRNA microRNA, MMP matrix metalloproteinase, OA osteoarthritis
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OA chondrocytes treated with EVs derived from FLS
exposed to IL-1β upregulate MMP-13 and ADAMTS-5
and downregulate type II collagen [25]. These findings
suggest that there is a positive feedback loop in the joint
space, between the FLS and the chondrocytes, that pro-
motes inflammation (Fig. 2). Additionally, EVs from IL-
1β-stimulated fibroblasts have an increased concentration
of IL-6, MMP-3, and VEGF [25]. When these EVs were
applied to mouse femoral cartilage explants, the IL-1β-
treated FLS EVs induced greater proteoglycan production
than the EVs from IL-1β-naïve FLS [25]. However,
both sets of EVs stimulated proteoglycan production
more than media without EVs [25]. The IL-1β-treated
FLS EVs also induced angiogenesis significantly more
than the EVs from FLS with no treatment [25].
MicroRNA profiling of EVs in OA
EVs from IL-1β-treated FLS were also profiled for differ-
ences in miRNA expression profiles. A total of 340 miR-
NAs were found to be upregulated in cells treated with
IL-1β while only 11 miRNAs were found to be upregu-
lated in the EVs, revealing selective packaging of miR-
NAs into EVs by the FLS [25]. Thirty-nine miRNAs
were found to be downregulated in the EVs while only
24 were downregulated in the cell [25]. Of the 11
miRNAs upregulated in the EVs, only five of them were
also upregulated in the cell [25]: miR-500B, miR-4454,
miR-720, miR-199b, and miR-3154. Among these, miR-
4454, miR-720, and miR-199b are the most well studied.
miR-199b is increased during chondrogenesis and is de-
creased during senescence of mesenchymal stem cells
[95]. miR-4454 is increased with TNF-α stimulation and
is a target of NF-κB [96]. miR-720 promotes cell migra-
tion but its study in relation to the musculoskeletal sys-
tem is limited [97].
We recently examined EVs from the synovial fluid of
patients with OA and without OA [98]. Neither the con-
centration (OA: 1.18 × 1010 particles/ml, n = 6; non-OA:
1.59 × 1010 particles/ml, n = 6) nor the size (OA: 0.128 μm,
n = 6; non-OA: 0.127 μm, n = 6) of nanoparticles differed
between the groups (Fig. 3a) [98]. Chondrocytes treated
with labeled EVs isolated from the synovial fluid of OA
patients indicate that synovial fluid-derived EVs are
readily endocytosed by chondrocytes (Fig. 3b) [98]. This
further suggests that EVs carrying miRNAs and other
cargo impacting chondrocyte cell death or ECM deg-
radation may contribute to the pathogenesis of OA.
Profiling of EV cargo by PCR array showed that miR-
200C was increased 2.5-fold in EVs from OA patients
[98]. This miRNA is known to be upregulated with
Fig. 2 Proposed mechanism of EV communication between FLS and chondrocytes in OA. EVs from FLS stimulated with inflammatory cytokines
in the synovial fluid are released into the synovial fluid act on chondrocytes to increase MMP-13 and ADAMTS-5. EVs from chondrocytes stimulated
with inflammatory cytokines are released into the joint space and increase MMP-13, COX-2, IL-1β, and TNF-α. This positive feedback cycle leads to
further breakdown of the articular cartilage ECM. COX-2 cyclooxygenase 2, ECM extracellular matrix, EV extracellular vesicle, miRNA microRNA, MMP
matrix metalloproteinase
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oxidative stress and targets the zinc finger binding tran-
scription factor ZEB1, resulting in repression of its
transcription [99]. ZEB1, also known as delta EF1, plays
a prominent role in maintaining articular cartilage in
adults and is expressed at high levels in articular cartil-
age [100]. Mice without Zeb1 have severe skeletal de-
formities, because this transcription factor is known to
participate in bone formation [101]. Interestingly, ZEB1
represses the type II collagen promoter and decreases
the levels of type II collagen transcription [102]. miR-
200c expression is suppressed by IL-6 and plays a role
in mitigating IL-6 mediated inflammation [103]. Trans-
fer of miR-200c represents one way in which FLS com-
municate with chondrocytes to maintain articular
cartilage and is a potential targetable mechanism to re-
duce inflammation and increase chondrocyte synthesis
of type II collagen. Future studies will be directed at
evaluating EV-derived miR-200c as a potential bio-
marker for tracking the development and progression
of OA (Table 2).
Extracellular vesicles as therapeutic vehicles for the
treatment of OA
miRNA regulation of chondrocyte-specific genes repre-
sents a potential therapeutic target for OA. Currently,
OA is generally managed with NSAIDs, behavioral mod-
ifications, and eventual replacement of the joint with
prosthesis. Existing therapeutic approaches are not
Fig. 3 a Concentration of EVs in synovial fluid (x axis) versus the average size of EVs (y axis). There was no significant difference in either measurement
between EVs from OA patients and EVs from normal patients. b Top row, chondrocytes treated with DAPI and unlabeled EVs; bottom row,
chondrocytes treated with DAPI and PKH67-labeled EVs. Left column, only DAPI labeling; middle column, only PKH67 labeling; right column,
combination of DAPI and PKH67 labeling. EV extracellular vesicle, OA osteoarthritis
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effective for altering progression of the disease, unlike
the disease-modifying agents used to treat RA. miRNA
regulation represents a novel therapeutic approach that
has the potential to halt the progression of the disease
by blocking the induction and actions of MMP-13 and
promoting chondrocyte health. Synovial joints present a
unique environment to deliver small molecule therapeu-
tics because they are largely isolated from the rest of the
body. This represents another advantage of using these
molecules to treat OA because the synovial fluid is a
relatively insulated space, which would limit the molecules
from being delivered systemically if the dosage was ad-
equately controlled. Additionally, with the recent identifi-
cation of a method to target FLS, there is already a method
to target synovial joints for therapeutics [79]. The identifi-
cation of a method to specifically target chondrocytes
would open up the possibilities of therapeutics even fur-
ther. miRNA is normally degraded in the joint space, but
EV delivery can improve the short-term stability of miRNA
by protecting these small mRNAs from breakdown. Previ-
ous studies have demonstrated that different miRNAs can
be loaded into human-derived EVs [104]. Suspension of
therapeutically altered EVs in a hydrogel-scaffold or chon-
droitin sulfate sponge could result in a stable long-term de-
livery system of miRNA to an isolated synovial joint.
Further studies need to be carried out to better define the
safest and most effective way to target this process.
Conclusions
Establishing biomarkers that can identify the develop-
ment of joint disease at the earliest stages will benefit
patients that may ultimately go on to develop RA and
OA. Most of the joint destruction in RA occurs early in
the disease and for this reason treatment is not delayed
until the onset of symptoms [105]. This underscores the
need for further research into EV profiling for RA pa-
tients. Because there is currently no cure for RA, identi-
fying the disease earlier and enrolling the patients in
treatment before the symptoms become severe is the
most useful way to prevent morbidity and mortality in
patients with RA. Additionally, the recent research in-
volving EV mediation of the immune system and inflam-
matory response further indicates the need for more
investigation into the role of EVs in RA. Future work
into the mechanism of EV-mediated immune response
modulation with regard to RA has the potential to not
only reveal meaningful discoveries into the pathogenesis
of disease, but also new ways to therapeutically target
the disease. Recent work into EVs has already revealed a
mechanism by which to target synovial membranes
using EVs [79]. Additional investigation needs to be
done regarding the utility of this delivery method with
the drugs currently available to treat RA.
The role of EVs in OA has provided a foundation to
potentially create novel nonsurgical, disease-modifying
treatments for OA. There are currently no therapeutic
interventions that can reverse the process of OA. Using
EVs to deliver specific miRNA known to reduce MMP-
13 production in the joint space could decrease the
amount of cartilage destruction, potentially tipping the
balance in favor of cartilage synthesis. While there is a
large amount of research regarding miRNA regulation of
MMP-13, more work needs to be done with regard to
the utility of EVs in reducing the destruction of ECM by
MMP-13. Additionally, EVs with miRNAs that are known
to promote chondrogenesis could help further increase
the concentration of chondrocytes and replace the dam-
aged chondrocytes. More research into the miRNA regu-
lation of chondrogenesis could identify a potential miRNA
formulation that increases chondrogenesis.
Crosstalk between the immune system and synovium
in RA, and crosstalk between the synovium and articular
cartilage in OA, are two important communication path-
ways that need further investigation to more fully under-
stand the pathophysiology of RA and OA. EVs appear to
be key messengers in these communication pathways,
and future studies of EVs associated with joint disease
may uncover new therapeutic opportunities and treatment
strategies. A better understanding of the mechanism of
EVs and the contribution of EVs to normal physiology and
pathology will require an improved classification system
for EVs and further standardization of the techniques used
to isolate EVs. Key steps toward improving this classifica-
tion have been made, such as the International Society for
Extracellular Vesicles minimum requirements for defin-
ition of EVs, EV protein composition databases, and im-
provement in isolation techniques. However, continued
commitment to this endeavor and collaboration between
the scientists in the field is required to further our under-
standing of this critical communication mechanism and
potential therapeutic revolution.
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